Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 42 pages report, published by Global Markets Direct

Keywords : Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Therapeutics, Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Pipeline Overview, Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Pipeline, Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Pipeline Assessment

Report ThumbnailJune-2017
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Pipeline Review, H1 2017

Summary

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Metabotropic glutamate receptor 7 is a protein encoded by the GRM7 gene. G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase.

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Report covers products from therapy areas Central Nervous System, Ear Nose Throat Disorders and Genetic Disorders which include indications Post-Traumatic Stress Disorder (PTSD), Anxiety Disorders, Acute Sensorineural Hearing Loss, Acute Stress Disorder, Attention Deficit Hyperactivity Disorder (ADHD), Autism, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Infantile Spasm (West Syndrome), Obsessive-Compulsive Disorder, Presbycusis, Status Epilepticus, Substance (Drug) Abuse and Visceral Pain.

The latest report Metabotropic Glutamate Receptor 7 - Pipeline Review, H1 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)
- The report reviews Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • List of Figures
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • List of Tables
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Addex Therapeutics Ltd, H1 2017
  • Pipeline by Aevi Genomic Medicine Inc, H1 2017
  • Pipeline by Bio-Pharm Solutions Co Ltd, H1 2017
  • Pipeline by Pragma Therapeutics SAS, H1 2017
  • Dormant Projects, H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Overview
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Companies Involved in Therapeutics Development
  • Addex Therapeutics Ltd
  • Aevi Genomic Medicine Inc
  • Bio-Pharm Solutions Co Ltd
  • Pragma Therapeutics SAS
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Drug Profiles
  • ADX-71743 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fasoracetam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JBPOS-0101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PGT-117 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize mGluR7 for Acute Sensorineural Hearing Loss and Presbycusis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Dormant Products
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
  • Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
  • Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
  • Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
  • Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
  • Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
  • Sep 01, 2016: PRAGMA Therapeutics and UK Ministry of Defences Center for Defence Enterprise collaborate to support preclinical research on innovative treatment for tinnitus
  • Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
  • Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
  • Apr 25, 2016: PRAGMA Therapeutics awarded first prize and £300,000 from UK charity Action on Hearing Loss to develop new drugs to treat Hearing Loss
  • Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases
  • Nov 23, 2015: The SEVEN4PTSD consortium led by PRAGMA Therapeutics awarded 2015 French ANR grant to further advance its mGlu7 program for Post-Traumatic Stress Disorder
  • Dec 20, 2012: Addex Scientists Discover And Characterize First Potent And Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 Receptor
  • Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectMetabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Pipeline Review, H1 2017Product ThumbnailMetabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Pipeline Review, H1 2017, Industry ReportProduct #: 829030
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved